ArticleNeurogenetics2026
Inhibition of EIF2S1 expression regulates the PI3K/AKT pathway to mediate apoptosis in glioma cells: an in vitro study.
Article in Neurogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is a malignant central nervous system tumor that poses a threat to patient survival. Eukaryotic translation initiation factor 2 subunit alpha (EIF2S1) is closely associated with the progression of multiple human cancers. This study aimed to investigate the effects of EIF2S1 on glioma cells and the underlying molecular mechanisms. We analyzed EIF2S1 expression in glioma tissues and cell lines. Small interfering RNA (siRNA) targeting EIF2S1 was constructed and transfected into glioma cell lines to silence EIF2S1 expression. We then evaluated cell proliferation, apoptosis, and metastatic capacity. Western blotting (WB) was used to determine the effect of EIF2S1 knockdown on the phosphorylation levels of PI3K and AKT. Finally, glioma cells were co-treated with the PI3K activator 740 Y-P to verify whether the PI3K/AKT pathway mediates the function of EIF2S1 in glioma cells. EIF2S1 was significantly up-regulated in glioma. Knockdown of EIF2S1 markedly inhibited glioma cell proliferation, promoted apoptosis, and suppressed metastatic potential. Western blot analysis indicated that EIF2S1 silencing significantly reduced the phosphorylation levels of PI3K and AKT. Moreover, 740 Y-P significantly reversed the inhibitory effect of si-EIF2S1 on glioma cells. Our in vitro findings suggeste that EIF2S1 contributes the malignant progression of glioma cells by regulating the PI3K/AKT pathway, providing a theoretical basis for future exploring EIF2S1 as a potentical therapeutic target for glioma.
Indexed as
Identifiers
42213196What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.